Cargando…

First results of the EORTC-SPECTA/Arcagen study exploring the genomics of rare cancers in collaboration with the European reference network EURACAN

PURPOSE: Rare cancers are defined by an incidence of <6 out of 100 000 cases per year. They are under-represented in clinical research including tumour molecular analysis. The aim of Arcagen is to generate a multinational database integrating clinical and molecular information of patients with ra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morfouace, Marie, Stevovic, Aleksandra, Vinches, Marie, Golfinopoulos, Vassilis, Jin, Dexter X., Holmes, Oliver, Erlich, Rachel, Fayette, Jerome, Croce, Sabrina, Ray-Coquard, Isabelle, Girard, Nicolas, Blay, Jean-Yves
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7709508/ https://www.ncbi.nlm.nih.gov/pubmed/33262201 http://dx.doi.org/10.1136/esmoopen-2020-001075

Ejemplares similares

EORTC SPECTA‐AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe
por: de Rojas, Teresa, et al.
Publicado: (2019)

Results of screening in early and advanced thoracic malignancies in the EORTC pan-European SPECTAlung platform
por: Morfouace, M., et al.
Publicado: (2022)

International clinical trials setting for rare cancers: organisational and regulatory constraints—the EORTC perspective
por: Shash, Emad, et al.
Publicado: (2013)

Diagnosis and Treatment of Pineal Region Tumors in Adults: A EURACAN Overview
por: Lombardi, Giuseppe, et al.
Publicado: (2022)

Molecular Characterization of Ovarian Yolk Sac Tumor (OYST)
por: Hodroj, Khalil, et al.
Publicado: (2021)

Central nervous system germ cell tumor, an archetypal AYA tumor and a model for pediatric and neuro-oncology collaboration, review from the EURACAN domain 10 group
por: Faure Conter, Cecile, et al.
Publicado: (2022)

Comment on “EURACAN/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach”
por: Vigneswaran, Wickii T., et al.
Publicado: (2020)

Diagnosis and Treatment of Peripheral and Cranial Nerve Tumors with Expert Recommendations: An EUropean Network for RAre CANcers (EURACAN) Initiative
por: Pellerino, Alessia, et al.
Publicado: (2023)

European Reference Network for rare adult solid cancers, statement and integration to health care systems of member states: a position paper of the ERN EURACAN
por: Blay, J.-Y., et al.
Publicado: (2021)

EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults
por: Frappaz, Didier, et al.
Publicado: (2021)

The Statistical Evaluation of Treatment and Outcomes in Head and Neck Squamous Cell Carcinoma Clinical Trials
por: Fortpied, Catherine, et al.
Publicado: (2019)

Salivary gland cancer: ESMO–European Reference Network on Rare Adult Solid Cancers (EURACAN) Clinical Practice Guideline for diagnosis, treatment and follow-up
por: van Herpen, C., et al.
Publicado: (2022)

Molecular Mechanisms of Kaposi Sarcoma Development
por: Karabajakian, Andy, et al.
Publicado: (2022)

Translation and validation of the EORTC brain cancer module (EORTC QLQ-BN20) for use in Iran
por: Khoshnevisan, Alireza, et al.
Publicado: (2012)

Development of an item bank for the EORTC Role Functioning Computer Adaptive Test (EORTC RF-CAT)
por: Gamper, Eva-Maria, et al.
Publicado: (2016)

Interpreting Within-Patient Changes on the EORTC QLQ-C30 and EORTC QLQ-LC13
por: Coon, Cheryl D., et al.
Publicado: (2022)

Safety and efficacy of Pazopanib in advanced soft tissue sarcoma: PALETTE (EORTC 62072) subgroup analyses
por: Cesne, Axel Le, et al.
Publicado: (2019)

INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: Van Den Bent, Martin, et al.
Publicado: (2020)

Cisplatin, vincristine and ifosphamide combination chemotherapy of metastatic seminoma: results of EORTC trial 30874. EORTC GU Group.
por: Fosså, S. D., et al.
Publicado: (1995)

Dutch utility weights for the EORTC cancer-specific utility instrument: the Dutch EORTC QLU-C10D
por: Jansen, Femke, et al.
Publicado: (2021)

Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma
por: van den Bent, Martin, et al.
Publicado: (2020)

Cytokine and angiogenic factors associated with efficacy and toxicity of pazopanib in advanced soft-tissue sarcoma: an EORTC-STBSG study
por: Sleijfer, S, et al.
Publicado: (2012)

Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
por: Ménétrier-Caux, Christine, et al.
Publicado: (2019)

Precision Medicine: From “Omics” to Economics towards Data-Driven Healthcare - Time for European Transformation
por: Lacombe, Denis, et al.
Publicado: (2017)

Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial
por: Blesius, Aurore, et al.
Publicado: (2011)

Memory in low-grade glioma patients treated with radiotherapy or temozolomide: a correlative analysis of EORTC study 22033-26033
por: Klein, Martin, et al.
Publicado: (2020)

Development of a questionnaire (EORTC module) to measure quality of life in patients with cholangiocarcinoma and gallbladder cancer, the EORTC QLQ-BIL21
por: Friend, E, et al.
Publicado: (2011)

Phase 1–3 of the cross‐cultural development of an EORTC questionnaire for the assessment of sexual health in cancer patients: the EORTC SHQ‐22
por: Oberguggenberger, Anne Sophie, et al.
Publicado: (2018)

International phase IV validation study of an EORTC quality of life questionnaire for testicular cancer patients: the EORTC QLQ-TC26
por: Sztankay, Monika, et al.
Publicado: (2018)

Risk of death of patients with cancer presenting with severe symptoms of infection, with or without documented COVID-19: In reply to van Dam et al.
por: Assaad, Souad, et al.
Publicado: (2020)

Interprofessional education and collaborative practice policies and law: an international review and reflective questions
por: Girard, Marie-Andrée
Publicado: (2021)

Cross-cultural development of an EORTC questionnaire to assess health-related quality of life in patients with testicular cancer: the EORTC QLQ-TC26
por: Holzner, Bernhard, et al.
Publicado: (2012)

Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC’s)
por: Bétrian, Sarah, et al.
Publicado: (2017)

Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 “CREATE” Trial
por: Lee, Che-Jui, et al.
Publicado: (2021)

Surgical management of melanoma: an EORTC Melanoma Group survey
por: Testori, A, et al.
Publicado: (2013)

Validation of EORTC IN-PATSAT 32 in Morocco: Methods and Processes
por: Obtel, Majdouline, et al.
Publicado: (2017)

Psychometric properties of the EORTC QLQ-C30 in Uganda
por: Naamala, Allen, et al.
Publicado: (2021)

Assessing measurement invariance in the EORTC QLQ-C30
por: van Roij, Janneke, et al.
Publicado: (2021)

The EORTC QLU-C10D: The Canadian Valuation Study and Algorithm to Derive Cancer-Specific Utilities From the EORTC QLQ-C30
por: McTaggart-Cowan, Helen, et al.
Publicado: (2019)

German value sets for the EORTC QLU-C10D, a cancer-specific utility instrument based on the EORTC QLQ-C30
por: Kemmler, Georg, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_09p7vu1ul5v0sleq3iolj60grj